Sabela Recalde

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Aditya Bardia, Sara M. Tolaney, Kevin Punie et al. · Annals of Oncology · 2021 · 299 citations · Full text

Medicine, Oncology, Pharmacology +16

Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?

Amparo García‐Tejedor, Sergi Fernández-González, Raúl Ortega et al. · Breast Cancer Research and Treatment · 2020 · 24 citations

Medicine, Oncology, Surgery +16

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

María Gión, Isabel Blancas, Patricia Cortez-Castedo et al. · Nature Medicine · 2025 · 20 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.

José Manuel Pérez García, María Gión, Manuel Ruíz‐Borrego et al. · Journal of Clinical Oncology · 2024 · 19 citations · Full text

Medicine, Oncology, Pharmacology +13

Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Sara A. Hurvitz, Sara M. Tolaney, Kevin Punie et al. · Cancer Research · 2021 · 18 citations

Medicine, Oncology, Pharmacology +17